Literature DB >> 20633611

Monoamine deficits in the brain of methyl-CpG binding protein 2 null mice suggest the involvement of the cerebral cortex in early stages of Rett syndrome.

M Santos1, T Summavielle, A Teixeira-Castro, A Silva-Fernandes, S Duarte-Silva, F Marques, L Martins, M Dierssen, P Oliveira, N Sousa, P Maciel.   

Abstract

Rett syndrome is a neurodevelopmental disorder caused by mutations in the methyl-CpG binding protein 2 gene (MECP2). Several neural systems are affected in Rett, resulting in an autonomic dysfunction, a movement disorder with characteristic loss of locomotor abilities and profound cognitive impairments. A deregulation of monoamines has been detected in the brain and cerebrospinal fluid of both Rett patients and a Rett syndrome murine model, the Mecp2 knock-out mouse. Our goal was to characterize the onset and progression of motor dysfunction in Mecp2(tm1.1Bird) knock-out mice and the possible neurochemical alterations in different brain regions potentially playing a role in Rett-like pathophysiology, at two different time-points, at weaning (3 weeks old) and in young adults when overt symptoms are observed (8 weeks old). Our results revealed significant age- and region-dependent impairments in these modulatory neurotransmitter systems that correspond well with the motor phenotype observed in these mice. At 3 weeks of age, male Mecp2 knock-out mice exhibited ataxia and delayed motor initiation. At this stage, noradrenergic and serotonergic transmission was mainly altered in the prefrontal and motor cortices, whereas during disease progression the neurochemical changes were also observed in hippocampus and cerebellum. Our data suggest that the deregulation of norepinephrine and serotonin systems in brain regions that participate in motor control are involved in the pathophysiology of Rett syndrome motor phenotypes. Moreover, we highlight the contribution of cortical regions along with the brainstem to be in the origin of the pathology and the role of hippocampus and cerebellum in the progression of the disease rather than in its establishment. Copyright 2010 IBRO. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20633611     DOI: 10.1016/j.neuroscience.2010.07.010

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  21 in total

1.  Selective rescue of heightened anxiety but not gait ataxia in a premutation 90CGG mouse model of Fragile X-associated tremor/ataxia syndrome.

Authors:  Hoanna Castro; Emre Kul; Ronald A M Buijsen; Lies-Anne W F M Severijnen; Rob Willemsen; Renate K Hukema; Oliver Stork; Mónica Santos
Journal:  Hum Mol Genet       Date:  2017-06-01       Impact factor: 6.150

2.  Serotonergic signalling suppresses ataxin 3 aggregation and neurotoxicity in animal models of Machado-Joseph disease.

Authors:  Andreia Teixeira-Castro; Ana Jalles; Sofia Esteves; Soosung Kang; Liliana da Silva Santos; Anabela Silva-Fernandes; Mário F Neto; Renée M Brielmann; Carlos Bessa; Sara Duarte-Silva; Adriana Miranda; Stéphanie Oliveira; Andreia Neves-Carvalho; João Bessa; Teresa Summavielle; Richard B Silverman; Pedro Oliveira; Richard I Morimoto; Patrícia Maciel
Journal:  Brain       Date:  2015-09-15       Impact factor: 13.501

3.  α1- and α2-adrenergic receptors in the retrotrapezoid nucleus differentially regulate breathing in anesthetized adult rats.

Authors:  Luiz M Oliveira; Thiago S Moreira; Fu-Shan Kuo; Daniel K Mulkey; Ana C Takakura
Journal:  J Neurophysiol       Date:  2016-06-15       Impact factor: 2.714

4.  What Gene Mutations Affect Serotonin in Mice?

Authors:  Richard C Tenpenny; Kathryn G Commons
Journal:  ACS Chem Neurosci       Date:  2017-04-27       Impact factor: 4.418

5.  Stride-level analysis of mouse open field behavior using deep-learning-based pose estimation.

Authors:  Keith Sheppard; Justin Gardin; Gautam S Sabnis; Asaf Peer; Megan Darrell; Sean Deats; Brian Geuther; Cathleen M Lutz; Vivek Kumar
Journal:  Cell Rep       Date:  2022-01-11       Impact factor: 9.423

6.  Alterations in the cholinergic system of brain stem neurons in a mouse model of Rett syndrome.

Authors:  Max F Oginsky; Ningren Cui; Weiwei Zhong; Christopher M Johnson; Chun Jiang
Journal:  Am J Physiol Cell Physiol       Date:  2014-07-09       Impact factor: 4.249

Review 7.  MECP2 disorders: from the clinic to mice and back.

Authors:  Laura Marie Lombardi; Steven Andrew Baker; Huda Yahya Zoghbi
Journal:  J Clin Invest       Date:  2015-08-03       Impact factor: 14.808

8.  Biogenic amines and their metabolites are differentially affected in the Mecp2-deficient mouse brain.

Authors:  Nicolas Panayotis; Adeline Ghata; Laurent Villard; Jean-Christophe Roux
Journal:  BMC Neurosci       Date:  2011-05-24       Impact factor: 3.288

9.  Long-lasting beneficial effects of central serotonin receptor 7 stimulation in female mice modeling Rett syndrome.

Authors:  Bianca De Filippis; Valentina Chiodi; Walter Adriani; Enza Lacivita; Cinzia Mallozzi; Marcello Leopoldo; Maria Rosaria Domenici; Andrea Fuso; Giovanni Laviola
Journal:  Front Behav Neurosci       Date:  2015-04-14       Impact factor: 3.558

10.  GABA and glutamate pathways are spatially and developmentally affected in the brain of Mecp2-deficient mice.

Authors:  Rita El-Khoury; Nicolas Panayotis; Valérie Matagne; Adeline Ghata; Laurent Villard; Jean-Christophe Roux
Journal:  PLoS One       Date:  2014-03-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.